A couple of the slides GK presented at the EGM point to the differences between the trials - the comparisons indicate the patients in the Lupin trial were 'no less advanced' in terms of their cancer vs the WARMTH study.
The 19.7 MOs has the chance to improve as further data is collected up until October this year.
GK also hinted at the potential to go up to 2400mg dosage in future trials .
He also indicated that he is "very comfortable" with the IP situation as the increasing data set allows for claims which a far more novel & inventive versus the initial patents lodged.
Ann: New Independent Trial Data Supports Potential of Veyonda, page-5
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $33.60M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.5¢ | $6.833K | 59.41K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 659373 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 56797 | 3 |
View Market Depth
| Last trade - 11.48am 04/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |